Catabolic fillers and methods for making same

Abstract

The present disclosure relates to a catabolic filling line and a preparation method thereof. The catabolic filling line provided according to the present disclosure is composed of poly-L-lactic acid, and the molecular weight of the poly-L-lactic acid is 30000 Da-150000 Da. The catabolic filling line of the present disclosure is composed of poly-L-lactic acid, which is absorbable, has no residue, and is metabolized in the human body to form lactic acid. Such a setting makes the catabolic filling line not only play a filling and tightening role itself when filling is performed using the catabolic filling line of the present disclosure, but also the lactic acid after its metabolism can still stimulate the fibroblasts of the skin and subcutaneous tissue to make the collagen framework in the human body be reconstructed by the fibroblasts, thereby long-term and continuously exerting the filling and tightening effect of the catabolic filling line.

Description

TECHNICAL FIELD

[0001] The present disclosure relates to the technical field of medical cosmetology materials, and particularly relates to a catabolic filling line and a preparation method thereof. BACKGROUND

[0002] With the development of society and the improvement of living standards, people's pursuit of beauty is getting higher and higher, which puts forward higher requirements for related technologies and materials in the medical beauty field. For example, in the aspect of filling and tightening, the number of people who start to try increases, and the parts that need to be filled also increase.

[0003] In the related art, the catabolic filling line used causes certain trauma to human tissues, and has postoperative side effects, resulting in poor user experience. SUMMARY

[0004] To overcome the problems in the related art, the present disclosure provides a catabolic filling line and a preparation method thereof.

[0005] According to a first aspect of an embodiment of the present disclosure, a catabolic filling line is provided, which is composed of poly-L-lactic acid, and the molecular weight of the poly-L-lactic acid is 30000 Da-150000 Da.

[0006] In an embodiment, the molecular weight of the poly-L-lactic acid is 30000 Da or 60000 Da. In an embodiment, the catabolic filling line includes a first segment and a second segment connected to each other, and the molecular weight of the poly-L-lactic acid of the first segment is less than that of the second segment.

[0007] In an embodiment, the first segment and the second segment have a connecting segment therebetween, and the length of the connecting segment is 0.5-5 mm.

[0008] In an embodiment, the diameter of the catabolic filling line is 90-200 μm, and the catabolic filling line is used to be implanted at the junction of the dermis layer and the subcutaneous tissue of the human body.

[0009] In an embodiment, the catabolic filling line is colorless or light white.

[0010] In an embodiment, the diameter of the catabolic filling line is 100-120 μm.

[0011] In an embodiment, the surface of the catabolic filling line is smooth.

[0012] In an embodiment, the tensile strength of the catabolic filling line is 25 CN-45 CN.

[0013] In an embodiment, the catabolic filling thread has an elongation of 25%-40%.

[0014] According to a second aspect of the embodiments of the present disclosure, a preparation method of a catabolic filling thread is provided, the preparation method comprising: spinning poly-L-lactic acid after dehydration and drying, and obtaining a catabolic filling thread after spinning; and stretching the catabolic filling thread and cooling to obtain the catabolic filling thread.

[0015] In an embodiment, the spinning poly-L-lactic acid after dehydration and drying, and obtaining a catabolic filling thread after spinning, comprises: dehydrating and drying the poly-L-lactic acid; spinning the dried poly-L-lactic acid at a temperature of 190-220°C, and obtaining the catabolic filling thread after spinning.

[0016] In an embodiment, the dehydrating and drying the poly-L-lactic acid comprises: dehydrating and drying the poly-L-lactic acid at a temperature of 65-110°C for 16-24 hours.

[0017] In an embodiment, the dehydrating and drying the poly-L-lactic acid comprises: dehydrating and drying the poly-L-lactic acid by means of a forced air drying oven.

[0018] In an embodiment, the stretching the catabolic filling thread and cooling to obtain the catabolic filling thread comprises: stretching the catabolic filling thread into a catabolic filling thread having a diameter of 100-120μm; and cooling and setting the stretched catabolic filling thread into the catabolic filling thread.

[0019] In an embodiment, the stretching the catabolic filling thread into a catabolic filling thread having a diameter of 100-120μm comprises: stretching the catabolic filling thread into the catabolic filling thread having a diameter of 100-120μm at a temperature of 70-85°C, wherein the stretching speed is 2-4 times the spinning speed.

[0020] The present disclosure further provides a catabolic filling thread, which is a thread composed of poly-L-lactic acid having a molecular weight of 30000Da-150000Da, and the catabolic filling thread has a diameter of 90-200μm, and is used for implanting into the dermis of a human body.

[0021] In an embodiment, the catabolic filling thread has a diameter of 100-180μm.

[0022] In an embodiment, the catabolic filling thread has a diameter of 100-150μm.

[0023] In an embodiment, the catabolic filling thread has a diameter of 110-130μm.

[0024] In an embodiment, the catabolic filler thread has a molecular weight of 50000 Da-130000 Da.

[0025] In an embodiment, the catabolic filler thread has a molecular weight of 60000 Da-120000 Da.

[0026] In an embodiment, the catabolic filler thread has a molecular weight of 80000 Da-100000 Da.

[0027] In an embodiment, the catabolic filler thread is a thread that is absorbed after 7 months after being implanted into the human body.

[0028] In an embodiment, the catabolic filler thread is a thread after the poly-L-lactic acid is dehydrated and dried and stretched.

[0029] The technical solutions provided by the embodiments of the present disclosure can include the following beneficial effects: the catabolic filler thread of the present disclosure is composed of poly-L-lactic acid, is absorbable, has no residue, and is metabolized into lactic acid in the human body. Such a setting makes the catabolic filler thread not only play a role in filling and tightening when the catabolic filler thread of the present disclosure is used for filling, but also the lactic acid after metabolism can still stimulate fibroblasts in the skin and subcutaneous tissue to use fibroblasts to reconstruct the collagen framework in the human body, thereby long-term and continuously exerting the filling and tightening effect of the catabolic filler thread.

[0030] It should be understood that the above general description and the following detailed description are only exemplary and explanatory, and cannot limit the present disclosure. BRIEF DESCRIPTION OF DRAWINGS

[0031] The accompanying drawings, which are incorporated into and form part of the specification, illustrate embodiments consistent with the present disclosure and, together with the specification, serve to explain the principles of the present disclosure.

[0032] Figure 1 is a structural schematic diagram of a catabolic filler thread according to an exemplary embodiment.

[0033] Figure 2 is a use state schematic diagram of a catabolic filler thread according to an exemplary embodiment.

[0034] Figure 3 is a flowchart of a preparation method of a catabolic filler thread according to an exemplary embodiment.

[0035] Figure 4 is a flowchart of a preparation method of a catabolic filler thread according to an exemplary embodiment.

[0036] Figure 5 is a flow chart of a preparation method of a catabolic filling line according to an example embodiment.

[0037] Figure 6 is a flow chart of a preparation method of a catabolic filling line according to an example embodiment.

[0038] Figure 7 is a flow chart of a preparation method of a catabolic filling line according to an example embodiment. DETAILED DESCRIPTION

[0039] The example embodiments will be described in detail herein with reference to the accompanying drawings. In the following description, unless otherwise indicated, like numbers in the different drawings represent similar or analogous elements. The following description of example embodiments is not representative of all embodiments consistent with the present disclosure. Rather, it is merely an example of devices and methods consistent with some aspects of the present disclosure as detailed in the appended claims.

[0040] With the development of society and the improvement of living standards, people's pursuit of beauty is getting higher and higher, which puts forward higher requirements for related technologies and materials in the medical beauty field. For example, in the aspect of filling and tightening, the number of people trying to start increases, and the parts that need to be filled also increase.

[0041] In the related art, the catabolic filling line used causes certain trauma to human tissues, and has postoperative side effects, resulting in poor user experience.

[0042] To overcome the problems in the related art, the present disclosure provides a catabolic filling line and a preparation method thereof.

[0043] The catabolic filling line provided by the present disclosure is composed of poly-L-lactic acid, and the molecular weight of the poly-L-lactic acid is 30000 Da-150000 Da.

[0044] The catabolic filling line of the present disclosure is composed of poly-L-lactic acid, which is absorbable, has no residue, and is metabolized to form lactic acid in the human body after metabolism. Such a setting makes the catabolic filling line not only play a role in filling and tightening when using the catabolic filling line of the present disclosure for filling surgery, but also the lactic acid after its metabolism can still stimulate fibroblasts in the skin and subcutaneous tissue, so that the fibroblasts can be used to reconstruct the collagen framework in the human body, thereby long-term and continuously exerting the filling and tightening effect of the catabolic filling line.

[0045] Figure 1 is a structural schematic diagram of a catabolic filling line according to an example embodiment. Figure 2is a use state diagram of a catabolic filler line according to an exemplary embodiment.

[0046] As shown in Figure 1 and Figure 2 The catabolic filler line 200 provided by the present disclosure can be composed of poly-L-lactic acid, i.e., the composition of the catabolic filler line of the present disclosure is 100% poly-L-lactic acid.

[0047] In recent years, a large number of medical literatures have clarified that lactic acid is an extremely important factor for the human body to regulate and activate fibroblasts in the skin and soft tissue, and the fibroblasts play a major role in rebuilding the support framework of the skin and subcutaneous tissue, i.e., the collagen microstructure. Therefore, when the catabolic filler line of the present disclosure is implanted into the human body, it also has the effect of stimulating the production of collagen when it is metabolized into lactic acid. The catabolic filler line in the related art does not have the effect of stimulating the production of collagen because it does not produce lactic acid during the metabolic process.

[0048] Therefore, after the catabolic filler line of the present disclosure is implanted into the human body, in addition to the effect of filling and tightening, after it produces lactic acid through metabolism, the lactic acid can be uniformly distributed to the skin and soft tissue to trigger the reconstruction of the autologous collagen framework, thereby achieving the effect of autologous filling. That is, lactic acid stimulates the production of collagen in the human body, and the produced collagen can play the role of filling.

[0049] In the present disclosure, the molecular weight of the poly-L-lactic acid can be 30000 Da-150000 Da. For example, in an embodiment, the molecular weight of the poly-L-lactic acid can be 30000 Da. In an embodiment, the molecular weight of the poly-L-lactic acid can be 60000 Da.

[0050] In the exemplary embodiment of the present disclosure, the diameter of the catabolic filler line can be 90-200 μm, and the catabolic filler line can be used to be implanted at the junction of the dermis and the subcutaneous tissue of the human body. Because the diameter of the catabolic filler line of the present disclosure is relatively small, when it is implanted at the junction of the dermis and the subcutaneous tissue, the catabolic filler line can be avoided to be seen on the surface of the skin. Specifically, if the diameter of the catabolic filler line exceeds this range, the catabolic filler line can be directly seen from the surface of the user's skin, which leads to a decrease in the aesthetic effect and fails to meet the requirements of the customers.

[0051] In addition, the diameter of the catabolic filler line of the present disclosure is relatively small, and the stimulation to the human tissue is small during the implantation process, and the foreign body sensation of the user is not obvious.

[0052] Specifically, the diameter of the catabolic filler line of the present disclosure is relatively thin, and thus can be implanted at the junction of the dermis and subcutaneous tissue. Fibroblasts mainly exist in the dermis, and thus, by implanting the catabolic filler line at the junction of the dermis and subcutaneous tissue, the lactic acid generated by the catabolic filler line can better stimulate the fibroblasts to generate collagen, thereby better playing a filling role.

[0053] In the present disclosure, the diameter of the catabolic filler line is relatively thin, and thus, in the case of implanting the catabolic filler line in the dermis, the outline of the catabolic filler line cannot be seen or felt on the surface of the skin of the user.

[0054] In addition, since the catabolic filler line of the present disclosure is relatively thin, after being implanted in the human body, the human body contains less poly-L-lactic acid per unit area, and thus the effective dose can be evenly distributed to the whole face, for example, different doses of the catabolic filler line can be injected at different positions of the whole face. If the diameter of the line exceeds the range of the present disclosure, the following problems may occur: the local dose is too high, the dose is not evenly distributed, or the ineffective metabolic product (PDO, PPDO line) cannot change the skin quality, or the local stimulation is excessive, and the like, resulting in scar formation.

[0055] In the present disclosure, the catabolic filler line can be colorless or light white, which can avoid the catabolic filler line being seen on the surface of the skin. Specifically, if the color of the catabolic filler line is relatively deep, the catabolic filler line can be directly seen from the surface of the skin of the user, which reduces the aesthetic effect and fails to meet the requirements of the customer.

[0056] In the exemplary embodiments of the present disclosure, the surface of the catabolic filler line can be smooth. Such a setting reduces the friction between the catabolic filler line and the human tissue during the filling and tightening operation, so that the catabolic filler line is more easily injected into the human body. During the injection process, the pain sensation of the user is also reduced, improving the user experience. In addition, after entering the human body, no damage to the human body is caused, no pain sensation of the user is increased, the user experience is improved, and there is no problem of subsequent postoperative side effects.

[0057] Specifically, the smooth catabolic filler line exists in the human body for a certain period of time after being injected into the human body, and moves with the tissues in the human body along with the activities or expressions of the human body. In this case, the smooth catabolic filler line does not pull the tissues in the human body, so the user does not feel pain caused by the pulling effect, thereby avoiding affecting the daily life of the user. The polylactic acid is metabolized in the human body to form lactic acid, and lactic acid also exists in the human body. The catabolic filler line of the present disclosure is composed of 100% polylactic acid, that is, the catabolic filler line of the present disclosure can be completely metabolized into lactic acid after being implanted into the human body, and finally can be metabolized into carbon dioxide and water, achieving zero residue in the human body and improving the safety of the product of the present disclosure.

[0058] For example, the catabolic filler line of the present disclosure can be metabolized and absorbed by the human body in less than or equal to 6 months or less than or equal to 7 months after being implanted into the human body. The actual absorption time is not limited in the present disclosure, and in actual situations, the metabolic absorption time of the catabolic filler line may vary depending on the diameter of the catabolic filler line, the length of implantation, and the implantation site.

[0059] In summary, the catabolic filler line composed of polylactic acid of the present disclosure not only can be used to fill the human body to achieve a tightening effect, but also can stimulate fibroblasts to generate collagen by using lactic acid produced by the metabolism of polylactic acid, thereby further improving the tightening effect. Moreover, the generated collagen can also play a filling role. Such a setting reduces the damage of the catabolic filler line to the human body, while achieving the effects of tightening and filling. Moreover, with the metabolism of the catabolic filler line, the filling and tightening effects of the catabolic filler line can be long-term and sustained.

[0060] The catabolic filler line of the present disclosure can include a first segment and a second segment connected to each other.

[0061] Polylactic acid is degraded into lactic acid in human tissues, and lactic acid stimulates fibroblasts in the tissue to reconstruct collagen microarchitecture, which is a key step to update the human skin and subcutaneous tissue. Therefore, polylactic acid is not a direct effective component when it acts in the human body. How much effect polylactic acid can exert is related to the total amount of lactic acid that can be degraded. The size of the molecular weight of polylactic acid affects the degradation rate. The smaller the molecular weight, the faster the degradation rate, and vice versa.

[0062] The size of the molecular weight can control the speed of lactic acid release, so in the same weight of poly-L-lactic acid, that is, the same final total effect, the same weight, but the smaller the molecular weight of the poly-L-lactic acid, the higher the short-term effect, but the effect release time is short. The molecular weight is high, the short-term effect is low, but the maintenance time is long. In the present disclosure, the catabolic filling line is set to two sections, namely the first section and the second section, and the first section and the second section adopt different molecular weights between each other. Such setting can control the realization of the role of some line sections (the first section or the second section) in the initial stage to quickly release the effect, and the role of some line sections (the second section or the first section) to slowly release the effect for a long time.

[0063] It should be pointed out that the present disclosure is not limited to including the first section and the second section. In some cases, more sections can also be included, and the molecular weights of these line sections can be different from each other.

[0064] In the present disclosure, the first section and the second section can have a connecting section. The connection between different molecular weight poly-L-lactic acid lines is best connected end to end. In order to minimize the pain felt when the needle and the line are placed in the skin, the side-by-side mode of two different molecular weight lines is not used, so as to increase the pain caused by the increase in the line diameter. In addition, the design can hide the joint end of the two line bodies in the needle body, avoiding the relatively rough connection that increases the friction with the skin.

[0065] In the present disclosure, the length of the connecting section can be 0.5mm-5mm. For example, in an embodiment, the length of the connecting section can be 1mm-3mm. In the present disclosure, the connecting section can use medical biological glue, for example, a-cyanoacrylate can be used, or other medical biological glue such as SUP-SDBS composite can be used.

[0066] In the present disclosure, poly-L-lactic acid with different molecular weights (10000-130KDa) can be used, two or more line sections with different molecular weights can be used, and the head-to-tail connection between them can be made with medical biological glue, in this case a-cyanoacrylate is used, and other medical biological glue such as SUP-SDBS composite can also be used.

[0067] In an exemplary embodiment of the present disclosure, the diameter R of the catabolic filling line can be 100-120μm. However, the present disclosure is not limited to this, and different choices can be made according to needs in actual use.

[0068] In the present disclosure, the catabolic filling line can be applied to various parts of the human body, such as the face, the torso, or the buttocks, etc. Specifically, different diameters of the catabolic filling line can be selected according to the different parts. For example, the catabolic filling line for the face can be relatively thin, which can be about 90 um, about 100 um, about 110 um, or about 120 um. The catabolic filling line applied to the buttocks can be relatively thick, for example, it can be about 150 um, about 160 um, about 170 um, about 180 um, about 190 um, or about 200 um.

[0069] In the present disclosure, the tensile strength of the catabolic filling line can be 2.0-4.0 cN / dtex (184-368 MPa). In the present disclosure, the elongation of the catabolic filling line is 25%-40%.

[0070] According to the above, the catabolic filling line of the present disclosure is composed of poly-L-lactic acid, which is metabolized into lactic acid after being injected into the human body. Lactic acid stimulates fibroblasts to produce collagen, thereby achieving a tightening effect. In this case, the requirement for the tensile strength of the catabolic filling line can be reduced, thereby reducing the process difficulty, making it easier to produce the catabolic filling line composed of poly-L-lactic acid, and improving the production efficiency of the catabolic filling line.

[0071] In the present disclosure, reducing the tensile strength of the catabolic filling line can avoid generating too high tensile force in some positions (such as the eye, the neck, the face, etc.), causing damage to the human tissue of these parts. On the other hand, reducing the tensile strength can avoid the catabolic filling line pulling the tissue of these parts, and after the metabolism of the catabolic filling line, causing the tissue to relax, reducing the duration of the effect of the catabolic filling line composed of poly-L-lactic acid.

[0072] As shown in Figure 2 In actual use, the catabolic filling line can be implanted by using a kit, for example, the catabolic filling line 200 can be pushed out of the needle 100 by pushing the needle tube 300 of the kit. The catabolic filling line 200 located outside the kit can be fixed by the fixing member 400.

[0073] Taking 30 subjects using the catabolic filling line of the present disclosure as an example, and taking 30 subjects using an implant line with a barb and a diameter larger than the diameter of the catabolic filling line of the present disclosure as a comparative example, the example and the comparative example were tested in the following aspects:

[0074] 1. Satisfaction, the number of subjects who are willing to receive a second operation at the same price after six months to one year is investigated. In actual use, the effect of such injection operation is maintained for a certain period of time, and is not permanent, so the subjects often need to perform multiple injections. Therefore, whether the subjects are willing to receive the injection operation again at the same price within a certain period of time is an important indicator for evaluating the satisfaction of the subjects with the first operation.

[0075] In the embodiment, 25 subjects received a second operation at the same price after six months to one year, while in the comparative example, only 1 subject received a second operation at the same price after six months to one year. It can be seen that the satisfaction of the subjects with the product is significantly higher than that with other implant lines.

[0076] 2. Comfort, the diameter of the catabolic filling line of the present disclosure is small, that is, the catabolic filling line is thin, which not only reduces the pain of operation, but also achieves uniform distribution of the dose and shortens the degradation time. After degradation, the foreign body sensation of the subjects is reduced, and the comfort is improved.

[0077] In the embodiment, only 2 subjects can feel or touch the existence of the line body within three days after receiving the operation. In the comparative example, 27 subjects can touch the line body three months after the operation, 12 subjects can touch the line body six months after the operation, and 7 subjects can feel the hard lump of the line nine months after the operation.

[0078] 3. Side effects, in the embodiment, only 2 subjects have a slight bulge at one position of the cheek due to expression changes after the operation, without pain, and the problem disappears without treatment within one week. In the comparative example, 6 subjects have the problem that the line body protrudes from the skin, which must be further treated by multiple debridement, and 7 subjects have different degrees of appearance changes caused by expression changes and the pulling of the line body.

[0079] 4. Postoperative recovery speed, in the embodiment, 30 subjects all resume the normal cleansing procedure, makeup, and skin care product use within two days after the operation. In the embodiment, 30 subjects no longer have a slight swelling feeling three days after the operation, and no visible ecchymosis after ten days. In the comparative example, 16 subjects still have swelling, pain, or ecchymosis reports one month after the operation.

[0080] Based on the same concept, the present disclosure can provide a preparation method of a catabolic filling line for manufacturing the catabolic filling line in the above embodiment. Figure 3 is a flowchart of a preparation method of a catabolic filling line according to an exemplary embodiment, as shown in Figure 3As shown, the preparation method of the present disclosure can include the following steps:

[0081] S11: After the poly-L-lactic acid is dehydrated and dried, spinning is performed, and after the spinning, a catabolic filling yarn is obtained.

[0082] S12: After the catabolic filling yarn is stretched, cooling is performed to obtain a catabolic filling thread.

[0083] The present disclosure adopts a melt spinning process, places the poly-L-lactic acid particles / powder into a melt extruder, and after extrusion and spinning by a screw, stretching is performed, so that the obtained poly-L-lactic acid tight catabolic filling thread has high strength, uniform and fine thread diameter, and causes less trauma to the tissue, thereby achieving better tight filling effect.

[0084] In an exemplary embodiment of the present disclosure, Figure 4 is a flow chart of a preparation method of a catabolic filling thread according to an exemplary embodiment, as shown in Figure 4 As shown, the preparation method of the present disclosure can include the following steps:

[0085] S21: The poly-L-lactic acid is dehydrated and dried.

[0086] In the present disclosure, the poly-L-lactic acid can be dehydrated and dried by a forced air drying oven.

[0087] S22: The dried poly-L-lactic acid is spun at a temperature of 170-220°C, and after the spinning, a catabolic filling yarn is obtained.

[0088] In the present disclosure, for example, the poly-L-lactic acid raw material can be dehydrated and dried and then added to a melt spinning machine, a melt spinning process is adopted, the poly-L-lactic acid particles / powder are placed into a melt extruder, and spinning is performed at a melt spinning temperature of 170-220°C. Specifically, the spinning mode can also be set to extrusion, for example, screw extrusion. In the present disclosure, the spinning can be performed at room temperature.

[0089] S23: After the catabolic filling yarn is stretched, cooling is performed to obtain a catabolic filling thread.

[0090] In the present disclosure, the obtained catabolic filling yarn is cooled to room temperature to obtain a poly-L-lactic acid tight catabolic filling thread, and the obtained poly-L-lactic acid tight catabolic filling thread is wound on a coil for standby. However, the present disclosure is not limited thereto, and in some embodiments, the obtained catabolic filling yarn can also be placed in a cooling device for cooling. After the catabolic filling thread is prepared, it can be wound on a coil for standby, or it can be wound on or stored in any component that is convenient for storage, storage or use.

[0091] In an exemplary embodiment of the present disclosure, Figure 5is a flow chart of a preparation method of a catabolic filling thread according to an exemplary embodiment, as shown in Figure 5 The preparation method of the present disclosure can include the following steps, as shown in

[0092] S31: dehydrating and drying the poly-L-lactic acid at a temperature of 65-110°C for 16-24 hours.

[0093] For example, in an embodiment, the temperature of the dehydrating and drying can be about 75°C, and the time of the dehydrating and drying can be about 16 hours.

[0094] S32: spinning the dried poly-L-lactic acid at a temperature of 170-220°C to obtain a catabolic filling thread.

[0095] S33: stretching and cooling the catabolic filling thread to obtain a catabolic filling thread.

[0096] In the exemplary embodiments of the present disclosure, Figure 6 is a flow chart of a preparation method of a catabolic filling thread according to an exemplary embodiment, as shown in Figure 6 The preparation method of the present disclosure can include the following steps, as shown in

[0097] S41: dehydrating and drying the poly-L-lactic acid at a temperature of 65-110°C for 16-24 hours.

[0098] S42: spinning the dried poly-L-lactic acid at a temperature of 170-220°C to obtain a catabolic filling thread.

[0099] S43: stretching the catabolic filling thread to have a diameter of 100-120μm.

[0100] S44: cooling and setting the stretched catabolic filling thread to obtain a catabolic filling thread.

[0101] In the exemplary embodiments of the present disclosure, Figure 7 is a flow chart of a preparation method of a catabolic filling thread according to an exemplary embodiment, as shown in Figure 7 The preparation method of the present disclosure can include the following steps, as shown in

[0102] S51: dehydrating and drying the poly-L-lactic acid at a temperature of 65-110°C for 16-24 hours.

[0103] S52: spinning the dried poly-L-lactic acid at a temperature of 190-220°C to obtain a catabolic filling thread.

[0104] S53: stretching the catabolic filling yarn into a catabolic filling yarn with a diameter of 100-120 μm, comprising: stretching the catabolic filling yarn into a catabolic filling yarn with a diameter of 100-120 μm at a temperature of 70-85 ℃, wherein the stretching speed is 2-4 times the yarn speed.

[0105] S54: cooling and setting the stretched catabolic filling yarn into a catabolic filling thread.

[0106] The catabolic filling thread of the present disclosure can fill and firm the skin through the action of the thread body, while degrading lactic acid to stimulate subcutaneous tissue fibroblasts to restore activity, thereby producing more collagen, elastin, and collagen fibers, making the skin more elastic in the subsequent process; in this process, the molecular structure of poly-L-lactic acid is gradually degraded and slowly hydrolyzed into lactic acid, and the degradation product lactic acid is converted into pyruvic acid under the action of lactate dehydrogenase, and then enters the mitochondria to be completely oxidized and decomposed to generate CO2 and H2O, which is replaced by new collagen. Compared with existing thread sculpting threads, it has a more long-acting and obvious cosmetic effect.

[0107] Example One

[0108] The present embodiment provides a poly-L-lactic acid firming catabolic filling thread, which has an effective component of poly-L-lactic acid, and the molecular weight of the poly-L-lactic acid is 30000 Da, and the thread diameter is 100-120 μm.

[0109] The preparation method of the poly-L-lactic acid firming catabolic filling thread provided in the present embodiment comprises the following steps:

[0110] The medical poly-L-lactic acid particles / powder is placed in a drying oven for drying and water removal, the drying time is 24 h, and the drying temperature is 16 ℃.

[0111] After drying, it is added to a melt spinning machine for spinning, the melt temperature of the spinning machine is adjusted to 190-220 ℃, the screw extrusion yarn is extruded, the yarn temperature is room temperature, and after extrusion, the obtained yarn diameter is 100-120 μm, and then it is cooled and set. The spinning temperature can be 200-220 ℃.

[0112] The present embodiment also provides a kit, taking 1000 pieces as an example, comprising:

[0113] 50 g of medical poly-L-lactic acid particles / powder with a molecular weight of 30000 Da;

[0114] 1000 needle handles and needle heads, the needle tube inner diameter of the needle head is 29G-38 mm;

[0115] 1000 foam balls;

[0116] The preparation method of the kit is as follows:

[0117] 50g of medical poly-L-lactic acid particles / powder is prepared into a poly-L-lactic acid firm and decomposing metabolism filling line by the preparation method provided in the embodiment, and the line segment with a uniform length of 40mm is cut;

[0118] The cut line segment is inserted into the needle tube of the needle, and each needle corresponds to one line segment; the length of the line segment remaining in the needle is 20-25mm;

[0119] The foam ball is sleeved on the outer wall of the needle to clamp the part of the line segment outside the needle, and then the needle protection sleeve is buckled, thereby obtaining the kit.

[0120] Example Two

[0121] The embodiment provides a poly-L-lactic acid firm and decomposing metabolism filling line and a kit, and the related parameters and the preparation method of the two are basically the same as those of example one, and the difference lies in that the molecular weight of the medical poly-L-lactic acid particles / powder used is 40000Da.

[0122] Example Three

[0123] The embodiment provides a poly-L-lactic acid firm and decomposing metabolism filling line and a kit, and the related parameters and the preparation method of the two are basically the same as those of example one, and the difference lies in that the molecular weight of the medical poly-L-lactic acid particles / powder used is 50000Da.

[0124] Example Four

[0125] The embodiment provides a poly-L-lactic acid firm and decomposing metabolism filling line and a kit, and the related parameters and the preparation method of the two are basically the same as those of example one, and the difference lies in that the molecular weight of the medical poly-L-lactic acid particles / powder used is 60000Da.

[0126] Example Five

[0127] The embodiment provides a poly-L-lactic acid firm and decomposing metabolism filling line and a kit, and the related parameters and the preparation method of the two are basically the same as those of example one, and the difference lies in that the molecular weight of the medical poly-L-lactic acid particles / powder used is 70000Da.

[0128] Example Six

[0129] The embodiment provides a poly-L-lactic acid firm and decomposing metabolism filling line and a kit, and the related parameters and the preparation method of the two are basically the same as those of example one, and the difference lies in that the molecular weight of the medical poly-L-lactic acid particles / powder used is 80000Da.

[0130] Example Seven

[0131] The embodiment provides a poly-L-lactic acid firming and decomposing metabolism filling line and a kit, and related parameters and a manufacturing method of the poly-L-lactic acid firming and decomposing metabolism filling line and the kit are basically same as those of the embodiment one, and the difference lies in that the molecular weight of the medical poly-L-lactic acid particles / powder used is 90000 Da.

[0132] Embodiment eight

[0133] The embodiment provides a poly-L-lactic acid firming and decomposing metabolism filling line and a kit, and related parameters and a manufacturing method of the poly-L-lactic acid firming and decomposing metabolism filling line and the kit are basically same as those of the embodiment one, and the difference lies in that the molecular weight of the medical poly-L-lactic acid particles / powder used is 100kDa.

[0134] Embodiment nine

[0135] The embodiment provides a poly-L-lactic acid firming and decomposing metabolism filling line and a kit, and related parameters and a manufacturing method of the poly-L-lactic acid firming and decomposing metabolism filling line and the kit are basically same as those of the embodiment one, and the difference lies in that the molecular weight of the medical poly-L-lactic acid particles / powder used is 110kDa.

[0136] Embodiment ten

[0137] The embodiment provides a poly-L-lactic acid firming and decomposing metabolism filling line and a kit, and related parameters and a manufacturing method of the poly-L-lactic acid firming and decomposing metabolism filling line and the kit are basically same as those of the embodiment one, and the difference lies in that the molecular weight of the medical poly-L-lactic acid particles / powder used is 130kDa.

[0138] Embodiment eleven

[0139] The embodiment provides a poly-L-lactic acid firming and decomposing metabolism filling line and a kit, and related parameters and a manufacturing method of the poly-L-lactic acid firming and decomposing metabolism filling line and the kit are basically same as those of the embodiment one, and the difference lies in that the molecular weight of the medical poly-L-lactic acid particles / powder used is 150kDa.

[0140] The poly-L-lactic acid firming and decomposing metabolism filling lines provided in the embodiments one to nine are respectively subjected to mechanical property testing, and the results are shown in Table 1.

[0141] Table 1 shows a comparison of mechanical properties of the poly-L-lactic acid firming and decomposing metabolism filling lines provided in the embodiments one to nine at a hot plate temperature of 70 DEG C and a hot plate temperature of 90 DEG C.

[0142]

[0143] Table 2 shows a comparison of mechanical properties of the poly-L-lactic acid firming and decomposing metabolism filling lines provided in the embodiments one to nine at a hot plate temperature of 80 DEG C and a hot plate temperature of 120 DEG C.

[0144]

[0145] The catabolic filling line of the present disclosure not only has the advantages of small side effects and good filling effect, but also has excellent tensile strength and shear strength. Considering that there may be some cutting and pulling actions in the subsequent use process, such tensile strength and shear strength make the application conditions of the catabolic filling line of the present disclosure wider and the use effect better.

[0146] It can be understood that the catabolic filling line provided by the embodiments of the present disclosure comprises the corresponding hardware structure and / or software module for executing each function in order to realize the above functions. In combination with the units and algorithm steps of each example disclosed in the embodiments of the present disclosure, the embodiments of the present disclosure can be realized in the form of hardware or a combination of hardware and computer software. Whether a certain function is executed by hardware or computer software driven hardware depends on the specific application and design constraints of the technical solution. Those skilled in the art can use different methods to implement the described functions for each specific application, but such implementation should not be considered beyond the scope of the technical solutions of the embodiments of the present disclosure.

[0147] It can be understood that “multiple” in the present disclosure refers to two or more, and other quantifiers are similar. “And / or” describes the association between the associated objects, which means that there can be three relationships, for example, A and / or B can represent the existence of A alone, the existence of A and B together, and the existence of B alone. The character “ / ” generally represents that the associated objects before and after are in an “or” relationship. The singular form “a”, “said” and “the” are also intended to include the plural form, unless the context clearly indicates otherwise.

[0148] It can be further understood that the terms “first”, “second”, etc. are used to describe various information, but these information should not be limited to these terms. These terms are only used to distinguish the same type of information from each other, and do not represent a specific order or importance. In fact, the expressions of “first”, “second”, etc. can be used interchangeably. For example, without departing from the scope of the present disclosure, the first information can also be referred to as the second information, and similarly, the second information can also be referred to as the first information.

[0149] It can be further understood that the terms “center”, “longitudinal”, “transverse”, “front”, “back”, “up”, “down”, “left”, “right”, “vertical”, “horizontal”, “top”, “bottom”, “inner”, “outer” and the like indicate the orientation or positional relationship based on the orientation or positional relationship shown in the drawings, and are only for the convenience of describing the embodiments and simplifying the description, and do not indicate or imply that the devices or elements referred to must have a particular orientation, be constructed and operated in a particular orientation.

[0150] It will be further understood that "connected" can include direct connection between two members or indirect connection between two members through other members.

[0151] It will be further understood that, unless otherwise specified, "connected" includes direct connection or indirect connection through others.

[0152] Other embodiments of the present disclosure will be apparent to those skilled in the art from consideration of the specification and practice of the application disclosed herein. It is intended that the present disclosure be considered as including any variations, uses, or adaptations of this application following, in general, the principles of the application and including such steps and inci- dents to the practice of the application as come within the purview of the prior art to which this application pertains. It is intended to cover by the claims appended hereto any and all adaptations or variations of this application. The specification and examples are to be construed as merely illustrative of the preferred embodiments of the present disclosure and not limitative of the scope of the disclosure. It is intended to cover by the patent claims appended hereto any and all adaptations or variations of this application.

[0153] It is to be understood that the application is not limited to the precise details of design and construction set forth above and illustrated in the drawings as modifications obvious to one skilled in the art are intended to be within the scope of the application. The scope of the application is limited only by the claims appended hereto.

Claims

1. A catabolic filler thread, characterized in that, The catabolic filling line is composed of poly-L-lactic acid with a molecular weight of 30000 Da-150000 Da, and includes a plurality of line segments connected to each other, the poly-L-lactic acid of the plurality of line segments has different molecular weights, the adjacent line segments have connecting segments, the line segments with different molecular weights are connected in an end-to-end form through the connecting segments, the connecting segments are medical biological glue, the length of the connecting segments is 0.5-5 mm, the length of the catabolic filling line is 40 mm, the diameter of the catabolic filling line is 90-200 μm, the catabolic filling line is used to be implanted at the junction of the dermal layer and the subcutaneous tissue of the human body, and the surface of the catabolic filling line is smooth.

2. The catabolic filling line according to claim 1, wherein the poly-L-lactic acid has a molecular weight of 30000 Da or 60000 Da.

3. The catabolic filling line according to claim 1, wherein the catabolic filling line includes a first segment and a second segment connected to each other, and the poly-L-lactic acid of the first segment has a smaller molecular weight than the poly-L-lactic acid of the second segment.

4. The catabolic filling line according to claim 3, wherein the first segment and the second segment have the connecting segment therebetween.

5. The catabolic filling line according to claim 1, wherein the catabolic filling line is colorless or light white.

6. The catabolic filling line according to claim 1, wherein the catabolic filling line has a tensile strength of 25 CN-45 CN.

7. The catabolic filling line according to claim 3, wherein the catabolic filling line has an elongation rate of 25%-40%. The preparation method comprises: dehydration and drying of the poly-L-lactic acid, spinning of the dried poly-L-lactic acid, and obtaining of the catabolic filling yarn after spinning; and stretching and cooling of the catabolic filling yarn to obtain the catabolic filling line, wherein the poly-L-lactic acid has a molecular weight of 30000 Da-150000 Da, the catabolic filling line includes a plurality of line segments connected to each other, the poly-L-lactic acid of the plurality of line segments has different molecular weights, the adjacent line segments have connecting segments therebetween, the line segments with different molecular weights are connected in an end-to-end form through the connecting segments, the connecting segments are medical biological glue, the length of the connecting segments is 0.5-5 mm, the length of the catabolic filling line is 40 mm, the diameter of the catabolic filling line is 90-200 μm, the catabolic filling line is used to be implanted at the junction of the dermal layer and the subcutaneous tissue of the human body, and the surface of the catabolic filling line is smooth. The dehydration and drying of the poly-L-lactic acid, spinning of the dried poly-L-lactic acid, and obtaining of the catabolic filling yarn after spinning comprise: dehydration and drying of the poly-L-lactic acid; 8. A method of preparing a catabolic filler thread, characterized in that, spinning of the dried poly-L-lactic acid at a temperature of 170-220 ℃, and obtaining of the catabolic filling yarn after spinning. The dehydration and drying of the poly-L-lactic acid comprise: dehydration and drying of the poly-L-lactic acid. ​ 9. The method of claim 8, wherein the catabolic filler yarn is prepared by the steps of: ​ ​ ​ 10. The method of claim 9, wherein the catabolic filler yarn is prepared by the steps of: ​ dehydration drying the poly-L-lactic acid at a temperature of 65-110°C for 16-24 hours.

11. The method of claim 10, wherein the catabolic filler yarn is prepared by the steps of: The dehydration drying of the poly-L-lactic acid comprises: dehydration drying the poly-L-lactic acid by a forced air oven.

12. The method of claim 9, wherein the catabolic filler yarn is prepared by the steps of: The cooling and setting of the catabolic filling yarn after stretching the catabolic filling yarn comprises: stretching the catabolic filling yarn into a catabolic filling yarn with a diameter of 100-120μm; cooling and setting the catabolic filling yarn after stretching.

13. The method for preparing the catabolic filler thread according to claim 12, characterized in that, The stretching of the catabolic filling yarn into a catabolic filling yarn with a diameter of 100-120μm comprises: stretching the catabolic filling yarn into a catabolic filling yarn with a diameter of 100-120μm at a temperature of 70-85°C, wherein the stretching speed is 2-4 times of the yarn speed.

Images